Talquetamab | Search results | NICE

Showing 1 to 5 of 5 results for talquetamab

Sort by

Talquetamab for treating relapsed and refractory multiple myeloma after 3 or more treatments (TA1114)
Evidence-based recommendations on talquetamab (Talvey) for treating relapsed and refractory multiple myeloma after 3 or more treatments in adults.
Result type
Technology appraisal guidance
Published
3 December 2025
View recommendations for TA1114
Show all sections
Sections for TA1114
Elranatamab for treating relapsed and refractory multiple myeloma after 3 or more treatments (managed access review of TA1023) [ID6653]
In development Reference number: GID-TA11956 Expected publication date: 28 January 2027
Result type
Technology appraisal guidance
Status
In development
Linvoseltamab for treating relapsed or refractory multiple myeloma after 3 or more treatments [ID6609]
In development Reference number: GID-TA11052 Expected publication date: 17 February 2027
Result type
Technology appraisal guidance
Status
In development
Talquetamab with daratumumab for treating relapsed or refractory multiple myeloma after 1 or more lines of treatment including a proteasome inhibitor and lenalidomide [ID6625]
Awaiting development Reference number: GID-TA11815 Expected publication date: TBC
Result type
Technology appraisal guidance
Status
Awaiting development
Talquetamab with pomalidomide or teclistamab for treating relapsed or refractory multiple myeloma after 1 or more treatments including an anti-CD38 antibody and lenalidomide [ID6629]
Awaiting development Reference number: GID-TA11830 Expected publication date: TBC
Result type
Technology appraisal guidance
Status
Awaiting development